Article thumbnail
Location of Repository

Testing the theory of immune selection in cancers that break the rules of transplantation

By A. Fassati and N.A. Mitchison


Modification of cancer cells likely to reduce their immunogenicity, including loss or down-regulation of MHC molecules, is now well documented and has become the main support for the concept of immune surveillance. The evidence that these modifications, in fact, result from selection by the immune system is less clear, since the possibility that they may result from reorganized metabolism associated with proliferation or from cell de-differentiation remains. Here, we (a) survey old and new transplantation experiments that test the possibility of selection and (b) survey how transmissible tumours of dogs and Tasmanian devils provide naturally evolved tests of immune surveillance

Topics: Transmissible, cancer, immune selection, epigenetic, occult tumour, tasmanian devils
Year: 2010
OAI identifier:
Provided by: UCL Discovery

Suggested articles


  1. (1876) Zur Frage uber die impfung der krebsigen geschwulste.
  2. A (2002) Bone marrow transplantation for paediatric AML in first remission: a systematic review and meta-analysis.
  3. (2007). A survey of H2 gene sequences, including new wild-derived genes.
  4. (2004). Absence of major histocompatibility complex class I on neural stem cells does not permit natural killer cell killing and prevents recognition by alloreactive cytotoxic T lymphocytes in vitro.
  5. (2007). Adaptive immunity maintains occult cancer in an equilibrium state.
  6. (2006). Allograft theory: transmission of devil facial-tumour disease.
  7. (1956). Antigens of heterozygous tumours as materials for the study of cell heredity.
  8. (2002). Cancer immunoediting: from immunosurveillance to tumor escape.
  9. (2000). Canine transmissible venereal tumour: a morphological and immunohistochemical study of 11 tumours in growth phase and during regression after chemotherapy.
  10. (2007). CD4? CD25? regulatory T cells in transplantation: progress, challenges and prospects.
  11. (2006). CD95L/FasL and TRAIL in tumour surveillance and cancer therapy.
  12. (2008). Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines.
  13. (2007). Characterization of major histocompatibility complex class I and class II genes from the Tasmanian devil (Sarcophilus harrisii).
  14. (2009). Chromosomal abnormalities and novel disease-related regions in progression from Barrett’s esophagus to esophageal adenocarcinoma.
  15. (1999). Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors.
  16. (2006). Clonal origin and evolution of a transmissible cancer.
  17. (2008). Combined immunogene therapy of IL-6 and IL-15 enhances anti-tumor activity through augmented NK cytotoxicity.
  18. (2007). Current concepts and perspectives of immunosuppression in organ transplantation.
  19. (2008). Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma.
  20. (1972). Detection of humoral antibody to the transmissible venereal tumour of the dog.
  21. (2004). Devils advocates Tasmanian. Devil facial tumor project.
  22. (2002). Effect of tumor infiltrating lymphocytes on the expression of MHC molecules in canine transmissible venereal tumor cells. Vet Immunol Immunopathol 87:19–27
  23. (2009). Effects of immunotherapy of IL-6 and IL15 plasmids on transmissible venereal tumor in beagles.
  24. (2009). Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets
  25. (2008). Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3.
  26. (2008). Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors.
  27. et al (2008) CTLA4 blockade expands FoxP3? regulatory and activated effector CD4? T cells in a dosedependent fashion.
  28. et al (2009) Deaf1 isoforms control the expression of genes encoding peripheral tissue antigens in the pancreatic lymph nodes during type 1 diabetes.
  29. (1997). Expression of immunoglobulin superfamily cell adhesion molecules on murine embryonic stem cells.
  30. (2008). Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers.
  31. Garcia-Lora A et al (2003) MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components.
  32. (1987). Growth stage dependent expression of MHC antigens on the canine transmissible venereal sarcoma.
  33. (2009). Heterogeneity in cancer: cancer stem cells versus clonal evolution.
  34. (2005). High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity.
  35. (2003). High-resolution sperm typing of meiotic recombination in the mouse MHC Ebeta gene.
  36. (2009). HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank.
  37. (2008). HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance.
  38. (2007). HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination.
  39. (2008). HLA-G-dependent suppressor cells: Diverse by nature, function, and significance.
  40. (2008). HLA-G: from biology to clinical benefits.
  41. (2001). Human reproductive failure II: immunogenetic and interacting factors. Hum Reprod Update 7:135–160
  42. (2009). Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy.
  43. (2007). Immune selective pressure and HLA class I antigen defects in malignant lesions.
  44. (1988). Immunobiology of a spontaneously regressive tumor, the canine transmissible venereal sarcoma (review).
  45. (1996). Immunohistochemical characterization of canine transmissible venereal tumor.
  46. (1998). Immunohistochemical study of the local inflammatory infiltrate in spontaneous canine transmissible venereal tumour at different stages of growth.
  47. (2009). Immunologically silent cancer clone transmission from mother to offspring.
  48. (1997). Immunophenotype of the canine transmissible venereal tumour.
  49. (2009). Immunosuppression for liver transplantation.
  50. (2009). Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
  51. (2006). Interferons, immunity and cancer immunoediting.
  52. Konigsrainer A (2008) Is IDO a key enzyme bridging the gap between tumor escape and tolerance induction? Langenbecks Arch Surg 393:995–1003
  53. (1984). Lack of beta 2-microglobulin on the surface of canine transmissible venereal tumor cells.
  54. (2009). Loss of mismatched HLA in leukemia after stem-cell transplantation.
  55. (2007). Loss or down-regulation of HLA class I expression at the allelic level in freshly isolated leukemic blasts.
  56. (2009). Multiplexed cell signaling analysis of metastatic and nonmetastatic colorectal cancer reveals COX2-EGFR signaling activation as a potential prognostic pathway biomarker.
  57. (2003). Neural progenitor cells lack immunogenicity and resist destruction as allografts.
  58. (2008). NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy.
  59. (2009). Origins and evolution of a transmissible cancer.
  60. (1957). Permanent modification (mutation?) of a histocompatibility gene in a heterozygous tumor.
  61. (2009). Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments.
  62. (2005). Regulation of CD4? CD25? regulatory T cell activity: it takes (IL-)two to tango.
  63. (2008). Regulation of tumor immunity: the role of NKT cells.
  64. (2008). Regulatory T cells and antigen-specific tolerance. Chem Immunol Allergy 94:8–15
  65. (2009). Role of the inhibitory KIR ligand HLABw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells.
  66. (2005). Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance.
  67. (2009). Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA1 as positive prognostic factors. PLoS One 4:e6412
  68. (2008). Tasmanian devil facial tumour disease: lessons for conservation biology.
  69. (2008). TGF-beta and tumors—an ill-fated alliance.
  70. (2001). The bare lymphocyte syndrome and the regulation of MHC expression. Annu Rev Immunol
  71. (1973). The biological behaviour of the transmissible venereal tumour in immunosuppressed dogs.
  72. (1985). The canine transmissible venereal tumor: a unique result of tumor progression.
  73. (1953). The genetics of transplantation.
  74. (2004). The immunobiology of cancer immunosurveillance and immunoediting.
  75. (2006). The role of HLA promoters in autoimmunity.
  76. (2002). The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 13:95–109
  77. (2007). Transmission of a fatal clonal tumor by biting occurs due to depleted MHC diversity in a threatened carnivorous marsupial.
  78. (2004). Tumor-infiltrating lymphocyte secretion of IL-6 antagonizes tumor-derived TGF-beta 1 and restores the lymphokine-activated killing activity.
  79. (2008). Twelve immunotherapy drugs that could cure cancers.
  80. (2006). Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.
  81. (2007). WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism?

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.